Position in SYRE
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$7,901
-$133,331 QoQ
Shares Held
89
-96.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#247
of 265 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ABS Direct Equity Fund LLC holds $377,735 across 10 Biotechnology names. SYRE ranks #7 (2.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RNTX |
Rein Therapeutics, Inc.
|
125,000 | $130,000 | |
| 2 | ACTU |
Actuate Therapeutics, Inc.
|
73,186 | $111,974 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
245 | $59,968 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
187 | $35,021 | |
| 5 | MIRM |
Mirum Pharmaceuticals, Inc.
|
117 | $13,697 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
97 | $9,455 | |
| 7 | SYRE |
Spyre Therapeutics, Inc.
This page
|
89 | $7,901 | |
| 8 | CYTK |
Cytokinetics Inc
|
85 | $7,241 |
All Filings in SYRE
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,901 | 89 | Shares | Other | 2026-08-13 | |
| 2026-03-31 | $141,232 | 2,800 | Shares | Other | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||